期刊文献+

患者报告结局(PRO)在临床疗效评价体系中的应用与思考 被引量:19

The Application of Patient Reported Outcome(PRO)in the Clinical Effects Evaluation System
暂未订购
导出
摘要 现代医疗模式的转变,使得患者对疾病的直接感受,对疗效的评价,成为临床决策和药物安全性评价的重要指标。而PRO量表的问世,使患者有机会真正参与到医疗过程中来,也为临床疗效评价及药物管理提供了珍贵资料。本文将通过什么是PRO、PRO的价值以及PRO的发展近况来对PRO做一个初步的介绍,以便为后来的研究者提供可能的帮助。 With the transformation of medical model, the directly feel of disease from patients,the evaluation of treatment response from patients become the important indexes of clinic decision--making and drug safety evaluation. The appearance of the scale of PRO, make patients have a chance to really involve in medical treatment process. Also provide a lot of valuable information for the evaluation of clinical effects and the drug management. This article will give a preliminary introduce through three aspects: what is PRO, the value and development of PRO in order to provide assistant information for the later researchers.
出处 《医学与哲学(B)》 2011年第12期1-3,共3页 Medicine & Philosophy(B)
基金 山西省科技基础条件平台建设项目 项目编号:2010091018
关键词 患者报告结局 量表评价 体系研究 patient reported outcomes{ PRO), scale valuation, system study
  • 相关文献

参考文献18

  • 1Wilke R J, Burke L B, Erickson P. Measuring treatment impact: a re- view of patient-- reported outcomes and other efficacy endpoints in ap- proved product labels[J]. Control Clin Trials, 2004,25 :535--552.
  • 2Acquadro C, Berzon R, Dubois D, Leidy N K, et al. PRO Harmo- nization Group: Incorporating the patient's perspective into clrug de- velopment and communication: an ad hoe task force report of the Patient--reported Outcomes(PRO) Harmonization Group meeting at theFood and Drug Administration, February 16,2001[J]. Value in Health,2003,6(5) :522--531.
  • 3The ERIQA Group: Assessing Treatment Impact Using Patient--Reported Outcomes (PROs) : Challenges in Study Design, Conduct and Analysis. Meeting Report (Paris, May 10--11, 2004)[J]. Pa- tient- Reported Outcomes Newsletter, 2005, 3(Special) : 1-- 16.
  • 4U.S. Department of Health and Human Services, FDA, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Re- search, Center for Devices and Radiologieal Health. Guidance for Indus- try--Patient Reported Outcome Measures: Use in Medical Product De- velopment to Support Labeling Claims[EB/OL]. (2009--03--07)[2011 12-- 121. http://www, hqlo. corn/content/4/1/79.
  • 5Lynda C Doward, Ari Gnanasakthy, Mary G Baker. Patient repor- ted outcomes: looking beyond the label claim. Health and Quality of Life Outcomes[J]. Health Qual Life Outcomes, 2010,8:89.
  • 6Clare Bradley. Feedback on the FDA's February 2006 draft guid- ance on Patient Reported Outcome (PRO) measures from a devel- oper of PRO Measures[J]. Health and Quality of Life Outcomes, 2006,4:78.
  • 7Department of Health. Our Health, Our Care, Our Say: A New Direction for Community Services[J]. White Paper, London , 2006:1--236.
  • 8Leong K P, Chong E Y, Kong K O, et al. Tan Tock Seng Hospital (TTSH) Lupus Study Group: Discordant assessment of lupus ac- tivity between patients and their physicians: the Singapore experi- ence[J]. Lupus,2010,19(1) :100--106.
  • 9Guadagnoli E, Ward P. Patient Participation in Decision Making [J]. SocSciMed,1998,47(3):329--339.
  • 10Institute of Medicine. Crossing the Quality Chasm--A New Health System for the 21st Century[M]. Washington,DC:National Acade- mies Press,2001 : 1 --8.

二级参考文献12

  • 1刘凤斌,方积乾,王建华.中医药临床疗效评价的探讨[J].中药新药与临床药理,2004,15(4):290-292. 被引量:94
  • 2HuntSM, McKerinaSP, McEwenJ, et al.The Nottingham Heaith Profile:subjective health status and medica eonsuhations[J].SoeSciMed, 1981,15(13):221-229.
  • 3Stewart AL, Ware JE.Measuring functional and well-being, the medical outcomes study approach [M]. Durham, N. C.:Duke University Press, 1992.
  • 4Bergner M, Bobbit RA, Pollard WE, et al. The sickness impact profile:validation of a health status measure [J]. MedCare.1976,14(1): 57-67.
  • 5FDA. Guidance for industry patient--reported outcome measures: use in medical product development to support labeling claims, draft guidance[J]. Health Oual Life Outcomes,2006,4: 79.
  • 6Patient Reported Outcomes Harmonization Group. Harmonizing patient reported outcomes issues used in drug development and evaluation[R/ OL]. [2010- 05 01]. http;//www, eriqa-project, com/pro-harmo/ home. html.
  • 7国家食品药品监督管理局.药品临床试验管理规范[R].北京:国家食品药品监督管理局,2003.
  • 8张艳宏,刘保延,刘志顺,王寅,訾明杰,何丽云,赵宏.PRO与中医临床疗效评价[J].中医杂志,2007,48(8):680-682. 被引量:72
  • 9张艳宏,刘保延,何丽云,訾明杰.病人报告的临床结局研究与实际应用[J].中西医结合学报,2008,6(11):1101-1104. 被引量:23
  • 10陈薇,刘建平.临床疗效研究中的患者报告结局[J].中国中西医结合杂志,2009,29(8):746-749. 被引量:29

共引文献42

同被引文献254

引证文献19

二级引证文献109

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部